Biocon features in the ASIA IP ELITE list for the fourth consecutive year
Biocon Biologics debuts on the ASIA IP ELITE 2019 list
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Mylan
Novartis gets US nod for long-delayed Amgen copycat
Novartis's biosimilar, called Ziextenzo, is aimed at helping cancer patients boost infection-fighting white blood cells during…
Mylan working with DCGI to launch new TB drug in India
Mylan will be in a position to launch the product in India soon after receiving approvals from DCGI," Mylan's Global President and…
Mylan to invest $1 billion in India on capex in six years
Currently Mylan has 21 facilities and 15,000 employees working in India Multinational drug company Mylan will invest $1 billion…
Eisai India and Mylan to commercialise teceris
The second eribulin brand in India, teceris aimed at expanding access to metastatic breast cancer patients in India
Big Pharma to get bigger, but what about patients?
The second patent cliff is around the corner, as patents for branded molecules with cumulative global sales of over $ 251 billion…
Panel discussion: From formulation development to commercialisation of complex generics: Challenges…
FDD Conclave, a one-of-its-kind platform for formulation development and drug delivery professionals, is a thought leadership…
Mylan and Biocon to present phase-III trastuzumab biosimilar data at ASCO annual meeting
HERITAGE study shows comparable efficacy, safety and immunogenicity to branded trastuzumab in HER2-positive metastatic breast…
Delhi HC refrains from staying single judge interim order over breast cancer drug by Biocon and…
The division bench of the high court, however, said the drug-makers may continue to sell their products under the brand names
Mylan Health Hackathon to host health hackathon in Bengaluru
The event will focus on better health for a better world Mylan will host a health hackathon at its Global Center in Bengaluru on…